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BETH E. WOLFE* 
INTRODUCTION 
Consider a child diagnosed with a rare and life-threatening disease.  
Now, consider a pharmaceutical manufacturer that has tested a drug 
and has evidence that it can cure that disease, but, while the Food 
Drug ses, 
the FDA has not approved the drug for this new use.  Would you 
ician to know about this?  Would you care how 
they learned about it?  Are you willing to leave it up to a busy physi-
cian to spend countless hours researching in hopes of finding some 
treatment that will work?  Is it reasonable to expect this?  Currently 
pharmaceutical manufacturers are restricted in their ability to      
promote uses of drugs that have not been approved by the FDA.1
Physicians are left to their own research to find possible drug     
treatments for some of their most challenging patient illnesses.2
Recent challenges in the court may be about to change this. 
Pharmaceutical manufacturers have been subjected to costly     
lawsuits for the truthful promotion of off-label uses of drugs that 
could save lives.3  The government has claimed billions of dollars 
from pharmaceutical companies in settlement of claims for alleged 
illegal promotion of uses of pharmaceuticals not approved by the 
                                                                                                                          
*Ms. Wolfe is a J.D. Candidate at North Carolina Central University School of 
Law. She received her B.S. from the University of Michigan  Dearborn, and her 
M.B.A. from the Open University Business School in the United Kingdom. 
1.Amarin Pharma, Inc. v. U.S. FDA, 119 F. Supp. 3d 196, 203 (S.D.N.Y. 2015). 
2.Id. at 200. 
3.C. Lee Ventola, MS, Off-Label Drug Information: Regulation, Distribution, 
Evaluation, and Related Controversies, 34(8) Pharmacy & Therapeutics 428-440, 
(2009), available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2799128/. 
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FDA.4  This has been achieved by a provision based on criminal   
misbranding under the Food, Drug, Cosmetic Act (FDCA).5  Any 
drug that has been put into market and has been misbranded subjects 
the manufacturer or their representative to penalties under the FDCA 
including fines and imprisonment.6
Drug companies are now fighting back.  In August 2015, the 
Southern District of New York granted Amarin Pharma a preliminary 
injunction preventing the FDA from prosecuting them for the       
promotion of drug usages that were not approved by the FDA.7
Amarin wanted to promote their drug Vascepa, approved for one  
patient population, for use by a different patient population for whom 
the drug was not yet approved by the FDA.8  Amarin had already 
completed testing that proved the effectiveness of this additional use, 
eness 
for this new population.9  Amarin argued that preventing promotion 
of truthful uses of their drugs is a violation of their free speech 
rights.10  The United States District Court for the Southern District of 
relief.11  This case is a victory for free speech and could expand the 
availability of truthful and valuable uses of approved drugs to       
physicians who might otherwise not have access.  It could enable 
crucial information to reach more physicians, so that they can use 
drugs in patients where t
otherwise be unknown.  The question is  does this open the door for 
a flood of pharmaceutical manufacturers promoting all tested uses of 
their product, or is it a trap for the unwary, allowing promotion of the 
uses, but opening up the potential for suits under the FDCA? 
This paper will look at the cases leading up to this decision, the   
arguments that have won and lost, and the implications for the future.  
It will examine if this is a victory for free speech or if it is a danger 
                                                                                                                          
4.Amarin Pharma, 119 F. Supp. 3d at 204. 
5.See 21 U.S.C.S. § 331 (LEXIS 2011) (amended 2015). 
6. Id. 
7.Amarin Pharma, 119 F. Supp. 3d at 237. 
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by usurping the authority of the FDA and allowing promotion       
directly to physicians.  It will also forecast the risks and rewards that 
can be expected going forward.  Will this put lifesaving cures into the 
hands of physicians to treat those with little hope and extend,        
improve, or save lives?  Or will it open the floodgates for the      
promotion of unapproved drugs, and fill the courts with lawsuits for 
years to come, examining the fine line between truthful and hopeful 
claims? 
This article first reviews the 2015 Amarin Pharma, Inc. v. United 
States FDA12 case and the events leading up to the challenge in court.  
It then provides the background and history on drug approval,       
labeling, and off label promotion, and the cases that have been settled 
based on FDA prosecution for promotion of off label uses of drugs.  
Next, it reviews the rationale behind the approval of the injunction 
sought by Amarin based on the United States v. Caronia13 case from 
2012. This case note then explores the benefits and arguments against 
expanding allowable promotion of off label uses of drugs.  Finally, it 
argues that while this is a victory for first amendment protection of 
free speech, drug makers should be wary of the risks of continued 
prosecution as the holding may be found to be fact specific to      
Amarin.
THE CASE
On May 7, 2015, Amarin Pharma, Inc. brought suit against the 
United States Food and Drug Administration (FDA) seeking an    
injunction against a threatened misbranding action under the Food, 
Drug, and Cosmetic Act (FDCA) for its promotion of a triglyceride 
lowering drug, Vascepa, for a use that was not approved by the 
FDA.14
Vascepa is a drug developed to improve cardiovascular health.15
In 2011, Amarin sought FDA approval for two uses of Vascepa.16
The first use was for treating adult patients with very high             
                                                                                                                          
12.Id. at 196. 
13.United States v. Caronia, 703 F.3d 149 (2d Cir. 2012). 
14.Amarin Pharma, 119 F. Supp. 3d at 198. 
15.Id. at 209. 
16. Id.
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hypertri 17  The second use was for treating patients 
with persistently high triglyceride levels between 200 and 499 mg/dL 
of blood and who were already on statin therapy.18  The first use   
received FDA approval on July 26, 2012.19  The FDA did not       
approve the second use, and it is this use that was at issue in the case.  
The FDA denied Amar though 
their studies proved that Vascepa was effective in reducing           
triglyceride levels, there were studies that questioned whether this             
subsequently reduced the risk of cardiovascular events.20
Vascepa has been shown to be effective in reducing triglyceride 
levels.21  FDA-approved studies have been done confirming this, and 
the FDA has agreed with this in correspondence with Amarin.22
Vascepa is also safe and can be safely used by people with severe 
hypertriglyceridemia.23  Amarin gained agreement with the FDA to 
conduct clinical trials testing whether Vascepa was effective for 
unap 24  Additionally, this agreement for testing included 
approval for testing other factors relevant to cardiovascular health.25
This study was called the ANCHOR Study.26  The agreement was an 
that if the study is done and the benchmarks set in the agreement are 
met, that the FDA would approve the drug.27  At that time, the FDA 
required, and Amarin agreed, that Amarin would later conduct a 
study on whether Vascepa could prevent major cardiovascular events 
in high-risk patients including those with persistently high            
triglycerides.28  This study was called the REDUCE-IT Study, and 





21.Id. at 213. 
22.Id. at 209. 
23. Id. 
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the agreement was the REDUCE-IT SPA Agreement.29  The FDA 
intended this later study to be underway to provide input before they 
would approve the use of Vascepa for this patient population.30
The ANCHOR study achieved its benchmark requirements and 
showed that Vascepa significantly reduced triglyceride levels in    
patient populations with persistently high triglycerides.31  However, 
after Amarin applied for approval for Vascepa for this use, the FDA 
determined, through a public advisory committee convened in       
October 2013, that while Vascepa reduced triglyceride levels in this 
patient population, this had no impact on reducing risks of            
cardiovascular events.32  As a result, despite Amarin meeting the 
benchmark terms in the ANCHOR study, the FDA rescinded the 
ANCHOR SPA agreement and would not approve Vascepa for usage 
in this population unless this correlation could be proven.33  The FDA 
claimed that other drugs that successfully reduced triglyceride levels 
had failed to yield a reduction in cardiovascular events.34  They 
claimed that reduction in cardiovascular events was a premise of the 
ANCHOR study, and, therefore, it was appropriate to rescind that 
SPA agreement.35 They further stated that if Amarin was able to 
show a reduction in cardiovascular events from the REDUCE-IT 
study, then these results could be used to satisfy the approval        
requirements.36
ANCHOR-SPA agreement through three successive levels of the 
FDA re 37
In addition to not approving Amarin for use for those with         
persistently high triglyceride levels, the FDA told Amarin that they 
would consider Vascepa to be misbranded under the FDCA 21 
U.S.C.A. § 352 (West 2013),38 if the FDA marketed it for this use 




32.Id. at 211. 




37.Id. at 211. 
38.See 21 U.S.C.S. § 352 (2007) (defines ways in which drugs will be deemed to 
be misbranded including false or misleading labels and packaging).
2016 BIOTECHNOLOGY & PHARMACEUTICAL LAW REVIEW 55
prior to any approval of this use.39  This was a clear threat of criminal 
litigation under FDCA § 331 (prohibited acts). 
On May 7, 2015 Amarin brought a first amendment challenge to 
the Southern District of New York claiming the FDA was prohibiting 
them from promoting truthful and non-misleading statements, citing 
the results from the ANCHOR study.40  Amarin claimed that the 
FDA restrictions on promotion significantly reduced their ability to 
provide truthful information to physicians so that physicians could 
determine whether to prescribe Amarin to patients with persistently 
high triglycerides. 41  Amarin claimed that these prohibitions were a 
violation of their first amendment rights to engage in truthful and 
non-misleading speech.42  Further, they claimed that they should be 
able to provide information about these trials and results and uses 
without fear of criminal litigation.43
holding in United States v. Caronia,44 and argued that drug          
manufacturers should be allowed to provide information that consists 
of solely truthful and non-misleading speech.45
While the FDA did attempt to make concessions allowing for some 
dissemination of information without the risk of criminal             
prosecution, they objected to the preliminary injunction.46  They   
offered that providing the results of the ANCHOR study would not 
put Amarin under threat of prosecution,47 but making statements 
about the off label use of Vascepa was a violation that directly struck 
                                                                                                                          
39.Amarin Pharma, 119 F. Supp. 3d at 212. 
40. Id.
41.See generally Off Label  and Investigational Use of Marketed Drugs, Biolog-
ics, and Medical Devices  Information Sheet, US Food and Drug Administration 
Regulatory Information, (Jan. 25, 2006), 
http://www.fda.gov/RegulatoryInformation/Guidances/ucm126486.htm  (The FDA 
does not regulate physicians in the prescribing of drugs, so they are able to       
prescribe drugs for usage that are not FDA approved.). 
42.Amarin Pharma, 119 F. Supp. 3d at 212. 
43.Id. at 213. 
44.See United States v. Caronia, 703 F.3d 149, 169 (2d Cir. 2012) (holding that 
the government cannot prosecute pharmaceutical manufacturers and their         
representatives under the FDCA for speech promoting the lawful, off-label use of 
an FDA-approved drug. ). 
45.Amarin Pharma, 119 F. Supp. 3d at 198. 
46.Id. at 216. 
47. Id.
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at the heart of the principles of the drug approval framework         
established by Congress in 1962.48  Further, the FDA claimed that 
bringing a misbranding claim on promotional statements would not 
o
use of a drug that was not deemed safe and effective by the FDA.49
The FDA argued that while their enforcement was to be based on 
speech alone, there are other crimes where criminal liability can    
attach where speech is the only act.50  These acts include jury       
tampering, blackmail, and insider trading.51
These arguments to obtain a preliminary injunction against any    
enforcement actions by the FDA against Amarin were heard on July 
7, 2015.52  In the hearing, the court considered the likelihood of    
success of the case on its merits and granted the preliminary         
injunction.53  The court held that a misbranding prosecution cannot 
be based on free speech and that Amarin may engage in truthful and 
non-misleading speech, and that based on the facts provided, the   
information they wish to promote about Vascepa is truthful and    
non-misleading.54
BACKGROUND
laws passed by Congress in 1938 to oversee the safety of food, drugs, 
and cosmetics.55  Congress gives authority to the FDA to oversee and 
enforce this act.56
and did not include safety or effectiveness.57  However, after some 
                                                                                                                          
48.Id. at 218. 
49. Id.
50.Id. at 224. 
51. Id. 
52.Id. at 219. 
53.Id. at 237. 
54. Id. 
55.Ventola, supra note 3, at 428. 
56.See 21 USCS §§ 301 et seq. 
57.Jerry Avorn,, Two Centuries of Assessing Drug Risks, 367 New Eng. J. Med. 
193, 195 (2012). 
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to protect the public from unsafe drugs.58  In 1937, more than 100 
children had been poisoned by a sulfanilamide preparation that used a 
substance known to be lethal.59  This resulted in a public that        
demanded that the FDA ensure that drugs were safe for the public.60
Then, in 1962, more than 10,000 children worldwide were born with 
Thalidomide.61  Public outcry led to further legislation, giving the 
FDA the rights to ensure drug effectiveness as well as drug safety.62
Obtaining FDA approval is a long, costly and complex process and 
it can take decades before a drug can be used in the market and     
prescribed by physicians.63  The labeling, marketing, and promotion 
of the drug in the market is limited to the FDA approved uses.64  If 
new uses are found but not FDA approved, the use is referred to as 
65  While promotion of off label uses is limited by the 
FDCA, off label prescribing by physicians is not.66  A physician may 
use their medical judgment to prescribe drugs for uses not approved 
by the FDA, but pharmaceutical companies cannot label or promote 
the drugs for those uses.67
Off label uses can be shared with physicians in limited ways.     
Scientific studies may be published by manufacturers in peer        
reviewed scientific journals or through presentation of journal       
articles, or through trainings and workshops through independent 
sources not funded and not sponsored or presented by the             




61.Id. at 196. 
62. Id. 
63.Fed. Drug Admin., The FDA s Drug Review Process: Ensuring Drugs Are Safe 
and Effective (Nov. 6, 2014),  
http://www.fda.gov/drugs/resourcesforyou/consumers/ucm143534.htm. 
64.Ventola, supra note 3, at 432. 
65.Amarin Pharma, 119 F. Supp. 3d at 200. 
66.John E. Osborn, Can I Tell You the Truth? A Comparative Perspective on Regu-
lating Off-Label Scientific and Medical Information, 10 Yale J. Health Pol y L. & 
Ethics 299, 303 (2010), Available 
at:http://digitalcommons.law.yale.edu/yjhple/vol10/iss2/2. 
67.Amarin Pharma, 119 F. Supp. 3d at 200. 
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manufacturer.68  To limit the promotion of off label uses, the FDA 
prohibits the introduction of new drugs into interstate commerce if 
their use has not been approved and the FDCA prohibits the         
misbranding of drugs.69
or mislead 70  While the FDCA defines labels as any material 
accompanying the drug,71  are more broadly 
defined as anything a representative of the company or the product 
might present with the drug, or about the drug, even if it does not 
accompany the drug itself.72  The FDA requires that pharmaceutical 
companies limit statements relating to the promotion of their drugs to 
the use for which the drug was approved.73  Therefore, off label use 
would never be allowed for new drugs, and promotion of off label 
uses for existing approved drugs are limited through the FDCA    
limitations on misbranding and information dissemination of         
unapproved uses. 
The FDA has litigated many cases against pharmaceutical        
manufacturers such as Allergan, GlaxoSmithKline, and Abbott that 
have violated the misbranding prohibition found in the FDCA.74
These cases have resulted in billions of dollars in criminal and civil 
settlements.75
A complaint was filed in 2007 against Allergan for off-label     
marketing of pharmaceuticals.76  Two other complaints followed in 
2008 and 2009, and in 2010, Allergan pled guilty and paid $600    
million in fines, including $375 million in criminal fines, and $225 
million in civil fines for the unlawful promotion of Botox®         
Therapeutic, for uses not approved as safe and effective by the 
FDA.77  Amongst such unapproved conditions are headache, pain, 
                                                                                                                          
68.Ventola, supra note 3, at 429. 
69.21 U.S.C.A. § 331 (West 2013). 
70.21 U.S.C.A. § 352 (West 2013). 
71.21 U.S.C.A. § 321 (West 2009). 
72.Food and Drugs, 21 C.F.R. § 202.1 (2009). 
73.21 U.S.C.A. § 331 (West 2015). 
74.Amarin Pharma, 119 F. Supp. 3d at 204. 
75. Id. 
76.Complaint, U.S. v. Allergan, Inc., No. 1-07-CV-1288 (D. Ga. Jun. 5, 2007). 
77.Dep t of Justice, Allergan Agrees to Plead Guilty and Pay $600 Million to Re-
solve Allegations of Off-Label Promotion of Botox® (Sept. 1, 2010),
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spasticity and juvenile cerebral palsy.78 Allergan was particularly 
egregious in its promotion for pain and headaches as they increased 
the number of staff-held workshops held for physicians and practices 
focused on diagnosing and billing for Allergan for these uses.79
In 2011, a complaint was filed against GlaxoSmithKline for, 
amongst other things, pro
80  In 2012, GlaxoSmithKline pled guilty 
and paid $3 billion to settle cases associated with promoting        
misbranded drugs including Paxil and Wellbutrin.81  In this case,   
although the FDA never approved Paxil for pediatric use, GSK was 
promoting Paxil depression in patients under age 18.82  GSK also was 
routinely promoting Wellbutrin for a wide variety of lucrative off 
label uses including weight-loss, sexual dysfunction, and ADHD and 
substance addictions.83  For these two drugs, GSK paid criminal fines 
of $757,387,200.84
Similarly, criminal charges were filed against Abbott Laboratories 
in 2012 for misbranding of Depakote.85  Abbot settled for $1.5     
million in 2012 for promoting uses of Depakote that were not 
deemed safe and effective by the FDA.86  Specifically they were 





80.Complaint, U.S. v. GlaxoSmithKline, PLC., C.A. No. 11-10398-RWZ (D. Mass. 
Oct. 26, 2011). 
81.Dep t of Justice, GlaxoSmithKline to Plead Guilty and Pay $3 Billion to Resolve 






85.Complaint, U.S. v. Abbott Laboratories, No. 1:12:CR26 (W.D. Va., May 7, 
2012). 
86.Dep t of Justice, Abbott Labs to Pay $1.5 Billion to Resolve Criminal & Civil 
Investigations of Off-label Promotion of Depakote, (May 6, 2012),  
http://www.justice.gov/opa/pr/abbott-labs-pay-15-billion-resolve-criminal-civil-
investigations-label-promotion-depakote. 
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promoting Depakote for the treatment of agitation in dementia      
patients and for schizophrenia.87
In addition to financial settlements for civil and criminal penalties, 
criminal charges have been brought against sales representatives for 
promotion of off label uses.  First amendment defenses against the 
FDA where criminal sentences have been levied are not always    
upheld based on a free speech argument.  In United States v. Caputo, 
a federal appeals court in Chicago rejected a First Amendment claim 
of a defendant sentenced to ten years in prison for marketing a     
medical device to hospitals.88  This medical device was similar to an 
approved device, but did not operate the same.89  The FDA had only 
approved the companion product that worked differently, and did not 
approve the new device for any use at all.90  The court held that this 
was not an off-label promotion, and thus was not a free speech issue 
that might receive constitutional protection under the first       
amendment.91  They held that this was simply an unlawful sale and 
upheld the criminal charges.92
More recently, however, there has been a case where the defendant 
has been convicted of criminal charges for unlawful promotion of 
drugs, and the courts held that preventing his promotion of the drugs 
violated the de 93  In this case, United
States v. Caronia in 2012, Caronia, a pharmaceutical sales            
representative, appealed a criminal conviction for promoting off-label 
uses of Xyrem, a prescription drug manufactured by Orphan Medical, 
Inc.94  Caronia was subjected to a $25 fine and 100 hours of       
community service.95  The Second Circuit rule
enforce
stating: 
pharmaceutical manufacturers and their representatives under the 






92.Id. at 940. 
93.United States v. Caronia, 703 F.3d 149, 152 (2d Cir. 2012). 
94. Id.
95.Id. at 160.
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FDCA for speech promoting the lawful, off-label use of an         
FDA- 96  The Second Circuit found the regulation is 
97  The government did not appeal this ruling, and set in play a     
holding that established the foundation from which Amarin was    
decided. 
AMARIN LEVERAGED THE CARONIA HOLDING
on the holding in Caronia. Amarin argued that promotion of off label 
uses of Vascepa was truthful speech, and the court in Caronia       
established that this was protected speech under the first         
amendment.98  The government argued that the holding in Caronia 
applied only to the facts and circumstances of that case and was not a 
general ruling.99  However, in Caronia, the court closely analyzed 
and then de
-label use.100  The court   
concluded he was, and vacated the conviction.101  By doing the free 
speech analysis, the court in Caronia was taking a categorical view of 
the case, rather than resting their holding based on any specific facts. 
The Caronia court held that the misbranding provisions in the FDCA 
could not reach into limiting truthful speech, which is protected by 
the first amendment.102  Given th
contention in Amarin that the Caronia holding was fact-based was 
not supported by the court.103
This holding, whether narrowly fact-based or broadly applicable, 
does not apply to all speech about uses of drugs.  The claims must be 
truthful and not misleading.  In Caputo, the uses that were promoted 
had not been substantiated by evidence or a study, but in Amarin,
there was a valid study and the uses promoted were true. In Amarin,
                                                                                                                          
96.Id. at 169.
97.Id. at 167. 
98.Amarin Pharma, 119 F. Supp. 3d at 219. 
99.Id. at 224. 
100.Caronia, 703 F.3d at 162. 
101.Id. at 169. 
102.Id. at 168. 
103.Amarin Pharma, 119 F. Supp. 3d at 224.
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the ANCHOR-SPA studies were completed and were valid and FDA 
approved studies.  Any claims they intended to use to promote 
Vascepa were based on valid studies and would be truthful, thus    
protected by the first amendment. 
IMPLICATIONS OF ALLOWING OFF LABEL PROMOTION
Benefits 
There are many advantages gained by allowing broader promotion 
of truthful, off label uses of drugs.  Even today, data studying 725 
million prescriptions showed that 20% of these prescriptions were for 
off label uses.104  Seventy percent of those 20%, or over 100 million 
prescriptions, were based on no or weak science.105  Still, physicians 
are choosing to prescribe based on information available to them, 
even without this foundation. 
Broader promotion allows data to be available to a wider range of 
physicians that might otherwise not have been able to do the research 
themselves.  Physicians cannot keep current on all new research 
available, even if they are published in journals.  There are many 
manufacturers and journals and a physician cannot reasonably be 
expected to know all possible uses of every medication.  Important 
studies that may apply to their patients may easily be missed.106
Another argument for allowing off label promotion is to encourage 
off-label promotion, manufacturers have little incentive to do        
research to support pa
fewer than 200,000 Americans such as ALS or cystic fibrosis).107
The market is small, and without the ability to promote the uses in 
orphan diseases, these drugs may not be known by physicians to be 
used in their practice to support patients with no other alternatives. 
                                                                                                                          
104.David C. Radley, Susan N. Finkelstein & Randall S. Stafford, Off-label      
Prescribing Among Office-Based Physicians, 166 Arch Intern Med 1021 (2006),   
available at http://archinte.jamanetwork.com. 
105.Id. 
106.Ventola, supra note 3, at 432. 
107.Id.
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More commonly, the argument for the promotion of off label uses 
prior to FDA approval is to provide early notification to physicians 
about uses that have been studied and proven.  Even with new and 
more efficient processes to fast-track drug approval, the process 
could take years, making effective treatments unavailable to patients 
who need them.108  The impact of this could be tragic.  Patients that 
could benefit from uses, validated by studies outside the FDA       
approval process, may die or decline significantly before the uses of 
the drugs are known.  In patients who have died, or where there is no 
reversal of disease progression possible, it would be tragic not to 
make these drug usages known to their physicians as early as        
possible to slow or prevent decline, manage symptoms, or prevent or 
delay death. 
Risks 
Despite these advantages, the unfettered promotion of even truthful 
information raises concerns. 
Promotion of drug uses through peer-reviewed articles may          
introduce unintended consequences that expose the profession to 
risks and vulnerabilities, and thus introduce safety risks to the public.  
These concerns include the risks of selective publication of only    
positive studies, the suppression of important safety data, ghost    
written articles, and increased focus on publishing for the purposes of 
promoting reprints for marketing.109
Other concerns are that while off label promotion will ensure 
broader availability of the alternative uses and data to physicians, it 
does not follow that physicians will do their own due diligence to 
seek out additional information or do further research.  In these cases, 
physicians may rely solely on the information provided by the     
pharmaceutical manufacturer where the FDA has not compelled more 
rigorous research and proof of effectiveness.  This may result in false 
confidence by physicians who may prescribe drugs that have limited 
effectiveness or pose other risks to the patient. 
                                                                                                                          
108.United States v. Caronia, 703 F.3d 149, 162 (2d Cir. 2012). 
109.Ventola, supra note 3, at 435. 
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There are also questions about whether the FDA has enough        
resources to ensure that this widespread promotion is based on    
truthful content.  The government does not have an unlimited amount 
of resources, and by not placing clearly defined limits on promotion, 
such as containing broad promotion to FDA approved uses of drugs, 
the public health may be at risk.110
Another concern is whether the ability to widely promote off-label 
uses of drugs provides a motivation for drug manufacturers to avoid 
doing extensive clinical trials required by the FDA prior to promoting 
to physicians.  There is concern that drug manufacturers may initially 
conduct trials for a narrower, less complex use of a drug, as a way to 
get the drug into market, and then promote the off-label uses without 
the extensive testing normally required.111  This situation occurred 
with Fenfluramine when it was used in combination with                 
Phentermine (fen-phen) for weight loss and resulted in thousands of 
people with heart valve damage.112  Fenfluramine was approved as an 
appetite suppressant, and there were not extensive clinical trials for 
the fen-phen combination that would have identified this risk and 
prevented this long term heart damage.113
Recent studies have shown that the risks are very real.  In a study 
published on November 2, 2015, in the journal JAMA Internal     
Medicine, researchers at McGill University in Toronto found that 
patients were fifty-four percent more likely to experience adverse 
events if they were prescribed a drug for off label use. 114  This is 
particularly concerning given the prevalence of off label prescriptions 
written. 
IS IT A TRAP? 
The pharmaceutical companies certainly find that the ruling in   
Amarin may benefit their ability to communicate the off-label,       
                                                                                                                          
110.Id. at 438. 
111.Id. at 431. 
112.Id. at 428 440. 
113.Id. 
114.Karen Pallarito, Beware Safety Risks Posed by Off-Label  Drug Use, 
HEALTHDAY, (Nov. 2, 2015), http://consumer.healthday.com/general-health-
information-16/prescription-drug-news-551/beware-safety-risks-posed-by-off-
label-drug-use-704854.html.
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unapproved truthful uses of drugs more broadly to the public and 
physicians.  With the ruling in Amarin, it appears that this speech is 
protected by the first amendment and the risk of prosecution and 
large fines is at least minimized. 
Shortly after the Amarin ruling, other pharmaceutical                
manufacturers began to seek relief from the threat of criminal      
prosecution similar to Amarin.  Pacira Pharmaceutical filed a       
complaint on September 8, 2015 in the same court regarding 
EXPAREL, Paci sthetic product, asking the court to de-
speech, and to declare an FDA warning letter arbitrary and            
capricious.115  The parties settled and the letter was withdrawn on         
December 14, 2015.116
Nonetheless, it is unclear how broad this ruling is.  While certainly 
a win for first amendment protected free speech, the ruling is one that 
protects truthful speech.  In the Amarin ruling, the court looked 
closely at the wording Amarin wished to use.117  The holding       
concluded that Amarin may promote truthful speech, but concluded 
this based on the evaluation of the information provided to the 
court.118  If pharmaceutical companies determine independently that 
their research can be conclusively viewed as truthful, are they then 
subject to similar judicial review?  Until this case concludes, or    
additional cases go forward, we will not know whether this ruling is 
fact specific to the Amarin case.  Companies that act based on this 
ruling without further judicial holdings are at risk for negative     
evaluations of their claims and losses in the courtroom.  Until the full 
precedential value of this holding is determined, drug makers should 
be wary of believing that this holding opens up broad off label     
promotion opportunities. 
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66 POST AMARIN: DRUG PROMOTION Vol. IX  
WHERE SHOULD THIS GO? 
The need for off label usage of drugs is inarguable.  Some studies 
have found that the frequency of off label prescribing of drugs is as 
much as 38.9% of all prescriptions.119   This varies by the type of 
medication, but there is no question that physicians find off label   
prescribing necessary.  Drug makers should be able to promote off 
label uses of drugs, but it must be done in a safe framework that is 
less onerous than the full path of FDA approval. 
Off label promotion of drugs should be limited to those uses where 
there is clear evidence to support the claims.  While the FDA has 
made progress in providing faster drug approval paths,120 there still 
must be a way to provide information to physicians for uses that have 
been found to be useful, particularly for orphan diseases, which may 
not normally have a broad enough impact on the population to invest 
in even the faster approval processes.  The FDA needs guidelines on 
what evidence pharmaceutical companies must provide when they 
promote off label uses and not limit the evidence to only FDA      
approved studies. 
Physicians must also have training or requirements through their 
licensing or medical societies to ensure they are doing proper         
diligence in investigating the uses of off label uses of drugs before 
prescribing, and are informing their patients of the off label uses and 
risks.  While malpractice risks provide some incentive to physicians 
to do further research before prescribing, desperation to help a patient 
or unmanageable workloads may mean that the ph
doing enough research to better understand the uses and risks before 
prescribing. 
Patients have a right to know about the medications that are     
available in the market that have evidence indicating that the        
medication could help them.  With this right to knowledge comes the 
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responsibility of the patients to ask about the supporting evidence of 
the drug use for their illness and learn of the risks. 
Off label marketing of drugs serves an important role in treating 
illnesses where there is no medication approved to help the patient.  
It should be allowed with a combination of regulation, information 
availability, and physician and patient education. 
THE PATH FORWARD
The parties in the Amarin case were issued an order on August 10, 
2015 to jointly submit the next steps to the court by August 28, 
2015.121  In response to that order, the parties asked the court for a 
stay until October 30, 2015, which was extended until December 17, 
2015 while they considered a settlement.122  This stay was later     
extended until February 17, 2016.123 A proposed stipulation and    
order of settlement was filed with the FDA on March 8, 2016.124  If 
ap
While this settlement may be approved soon, the question remains 
whether the approval of the injunction has precedential value.  On 
this subject, they then will have settled with Amarin, and with Pacira.   
It seems that they will attempt to settle where they are challenged in 
an effort to delay firmer grounding in the expansion of off label          
promotions. 
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